Microbiome

Introduction

Microbiome is an important component in the neurobiology of neurodegenerative [diseases. This page provides detailed information about its structure, function, and role in disease processes. ^{<a href="#ref-1">[1]</a>} [@cryan2019]

Overview

The gut microbiome comprises the trillions of microorganisms residing in the gastrointestinal tract, including bacteria, archaea, fungi, and viruses. Emerging research has established bidirectional communication between the gut and brain through the [gut-brain-axis](/gut-brain-axis), with profound implications for neurodegenerative diseases including [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/amyotrophic-lateral-sclerosis), and [huntington-pathway](/mechanisms/huntington-pathway). The gut microbiome has been identified as a fundamental regulator of brain health, with disturbances in microbial composition (dysbiosis) linked to [neuroinflammation](/mechanisms/neuroinflammation), [protein-aggregation](/mechanisms/protein-aggregation), [blood-brain-barrier](/entities/blood-brain-barrier) dysfunction, and cognitive decline ([Cryan et al., 2019](https://doi.org/10.1152/physrev.00018.2018). ^{<a href="#ref-2">[2]</a>} [@zhu2024]

Introduction

Microbiome is an important component in the neurobiology of neurodegenerative [diseases. This page provides detailed information about its structure, function, and role in disease processes. ^{<a href="#ref-1">[1]</a>} [@cryan2019]

Overview

The gut microbiome comprises the trillions of microorganisms residing in the gastrointestinal tract, including bacteria, archaea, fungi, and viruses. Emerging research has established bidirectional communication between the gut and brain through the [gut-brain-axis](/gut-brain-axis), with profound implications for neurodegenerative diseases including [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/amyotrophic-lateral-sclerosis), and [huntington-pathway](/mechanisms/huntington-pathway). The gut microbiome has been identified as a fundamental regulator of brain health, with disturbances in microbial composition (dysbiosis) linked to [neuroinflammation](/mechanisms/neuroinflammation), [protein-aggregation](/mechanisms/protein-aggregation), [blood-brain-barrier](/entities/blood-brain-barrier) dysfunction, and cognitive decline ([Cryan et al., 2019](https://doi.org/10.1152/physrev.00018.2018). ^{<a href="#ref-2">[2]</a>} [@zhu2024]

Early microbiome changes have been detected in preclinical [alzheimers](/diseases/alzheimers-disease) patients and prodromal [parkinsons](/diseases/parkinsons-disease) patients, suggesting that gut dysbiosis may contribute to disease initiation rather than simply being a consequence of neurodegeneration ([Zhu et al., 2024](https://doi.org/10.1038/s41392-024-01743-1). ^{<a href="#ref-3">[3]</a>} [@qin2010]

Gut Microbiome Composition

Bacterial Diversity

The human gut contains: [@vogt2017]

• Over 1,000 bacterial species
• 10-100 trillion microorganisms (comparable in number to human cells)
• Dominated by the phyla Firmicutes and Bacteroidetes (~90% of total)
• Significant inter-individual variation shaped by [genetics](/mechanisms/genetics), diet, and environment
• Approximately 3.3 million non-redundant microbial [genes ([Qin et al., 2010](https://doi.org/10.1038/nature08821) ^{<a href="#ref-4">[4]</a>}

Key Bacterial Groups Relevant to Neurodegeneration

| Bacterial Group | Role | Relevance to Neurodegeneration | [@scheperjans2015]
|----------------|------|-------------------------------| [@sampson2016]
| Lactobacillus | Probiotic; GABA production | Reduced in AD and PD patients | [@minter2016]
| Bifidobacterium | SCFA production; immune modulation | Reduced in AD; associated with cognitive function | [@braak2003]
| Faecalibacterium prausnitzii | Major butyrate producer; anti-inflammatory | Depleted in PD and [multiple-sclerosis](/diseases/multiple-sclerosis) | [@cattaneo2017]
| Akkermansia muciniphila | Mucin degradation; barrier integrity | Altered in PD; emerging therapeutic target | [@aho2019]
| Prevotella | Fiber degradation | Dramatically reduced in PD | [@svensson2015]
| Enterobacteriaceae | Pro-inflammatory; LPS production | Elevated in AD and PD dysbiosis |
| Desulfovibrio | Hydrogen sulfide production | Elevated in PD; may promote [alpha-synuclein](/proteins/alpha-synuclein) aggregation | ^{<a href="#ref-5">[5]</a>}

Gut-Brain Axis Communication Pathways

The gut and brain communicate through multiple interconnected pathways, collectively termed the [gut-brain-axis](/gut-brain-axis) ([Cryan et al., 2019](https://doi.org/10.1152/physrev.00018.2018): ^{<a href="#ref-6">[6]</a>}

Neural Pathways

• Vagus nerve: The primary neural conduit between the enteric nervous system and the CNS. Vagotomy reduces PD risk in epidemiological studies, suggesting bottom-up propagation of pathology
• Enteric nervous system (ENS): The "second brain" containing ~500 million [neurons](/entities/neurons) that independently regulate gut function
• Neurotransmitter production: Gut bacteria synthesize ~95% of the body's [serotonin](/entities/serotonin), plus GABA, [dopamine](/entities/dopamine), [acetylcholine](/entities/acetylcholine), and [norepinephrine](/entities/norepinephrine) ^{<a href="#ref-7">[7]</a>}

Metabolite Pathways

• Short-chain fatty acids (SCFAs): Butyrate, propionate, and acetate produced by bacterial fermentation of dietary fiber. SCFAs regulate microglial maturation and function, maintain [blood-brain-barrier](/entities/blood-brain-barrier) integrity, and modulate neuroinflammation
• Trimethylamine N-oxide (TMAO): Gut-derived metabolite linked to increased neuroinflammation, [amyloid-beta](/proteins/amyloid-beta) deposition, and tau] phosphorylation. TMAO crosses the [blood-brain-barrier](/entities/blood-brain-barrier)
• Tryptophan metabolites: Bacterial tryptophan metabolism produces kynurenine, quinolinic acid (neurotoxic), and indole derivatives that modulate aryl hydrocarbon receptor signaling in [astrocytes](/cell-types/astrocytes)
• Bile acid metabolism: Secondary bile acids produced by gut bacteria act as signaling molecules affecting neuroinflammation via FXR and TGR5 receptors ^{<a href="#ref-8">[8]</a>}

Immune Pathways

• Gut-associated lymphoid tissue (GALT): The body's largest immune organ; regulates systemic immune tone
• Intestinal permeability ("leaky gut"): Dysbiosis-driven barrier breakdown allows bacterial products (LPS) to enter systemic circulation, promoting peripheral and central inflammation
• Toll-like receptor (TLR) signaling: Bacterial lipopolysaccharide (LPS) activates [tlr4](/entities/tlr4) on [microglia](/cell-types/microglia) pathology originates in the enteric nervous system and propagates to the brain via the vagus nerve:
• [alpha-synuclein](/proteins/alpha-synuclein) aggregates are found in the ENS of PD patients years before diagnosis
• Vagotomy reduces PD risk by ~40% in large epidemiological studies
• Injection of [alpha-synuclein](/proteins/alpha-synuclein) fibrils into the gut wall of mice leads to brain pathology via vagal transport
• Gut inflammation may trigger [alpha-synuclein](/proteins/alpha-synuclein) misfolding in enteric [neurons](/entities/neurons) ^{<a href="#ref-9">[9]</a>}

Constipation as an Early Biomarker

Constipation and other GI symptoms precede PD motor symptoms by 10-20 years and correlate with ENS alpha, supporting the gut-origin hypothesis. ^{<a href="#ref-10">[10]</a>}

Microbiome in Other Neurodegenerative Diseases

ALS

[als](/diseases/amyotrophic-lateral-sclerosis) patients show gut dysbiosis with reduced Ruminococcaceae and Faecalibacterium, and increased Enterobacteriaceae. In SOD1-mutant mice, protective gut bacteria (Akkermansia muciniphila) produce nicotinamide that delays disease progression. ^{<a href="#ref-1">[1]</a>}

Huntington's Disease

[huntington-pathway](/mechanisms/huntington-pathway) patients show altered gut microbiome composition with increased intestinal permeability. Mutant [huntingtin](/proteins/huntingtin) expression in the ENS may contribute to GI dysfunction. ^{<a href="#ref-2">[2]</a>}

Multiple Sclerosis

MS patients consistently show reduced Prevotella and Clostridia, with increased Methanobrevibacter. FMT from MS patients to germ-free mice induces autoimmune CNS pathology. ^{<a href="#ref-3">[3]</a>}

Therapeutic Interventions

Probiotics

Clinical trials of probiotic formulations in AD and PD patients have shown:

• Improved cognitive scores (MMSE) in AD patients receiving Lactobacillus/Bifidobacterium combinations
• Reduced inflammatory markers (CRP, IL-6) in PD patients
• Improved constipation and GI symptoms in PD ^{<a href="#ref-4">[4]</a>}

Prebiotics and Dietary Interventions

• High-fiber diets increase SCFA-producing bacteria and reduce neuroinflammation
• Mediterranean diet adherence correlates with healthier gut microbiome and reduced dementia risk
• Polyphenol-rich foods (berries, green tea) promote growth of anti-inflammatory gut bacteria ^{<a href="#ref-5">[5]</a>}

Fecal Microbiota Transplantation (FMT)

FMT is being investigated as a therapeutic approach:

• Small [clinical trials in PD patients show improved motor symptoms and constipation after FMT
• Case reports describe cognitive improvement in AD patients post-FMT
• Larger randomized controlled trials are underway (as of 2025) ^{<a href="#ref-6">[6]</a>}

Postbiotics and Metabolite-Based Therapies

• Sodium butyrate supplementation improves [blood-brain-barrier](/entities/blood-brain-barrier) integrity and reduces neuroinflammation in animal models
• TMAO-lowering strategies (e.g., 3,3-dimethyl-1-butanol) reduce AD pathology in mice
• Indole-3-propionic acid (IPA), a bacterial tryptophan metabolite, shows neuroprotective effects ^{<a href="#ref-7">[7]</a>}

Challenges and Future Directions

• Causality vs. correlation: Most human studies are cross-sectional; prospective longitudinal studies are needed
• Individual variability: Gut microbiome composition varies widely between individuals, complicating therapeutic standardization
• Mechanistic specificity: Many proposed mechanisms lack definitive proof in humans
• Therapeutic optimization: Optimal probiotic strains, doses, and treatment duration remain undefined
• Biomarker development: Establishing gut microbiome signatures as diagnostic or prognostic biomarkers for neurodegeneration ^{<a href="#ref-8">[8]</a>}

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
• [Human Microbiome Project](https://hmpdacc.org/) — NIH microbiome data
• [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data ^{<a href="#ref-9">[9]</a>}

Background

The study of Microbiome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration and continues to drive therapeutic development. ^{<a href="#ref-10">[10]</a>}

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. ^{<a href="#ref-1">[1]</a>}

Brain Atlas Resources

• Allen Human Brain Atlas: [Microbiome expression search](https://human.brain-map.org/microarray/search/show?search_term=Microbiome)
• Allen Mouse Brain Atlas: [Microbiome search](https://mouse.brain-map.org/search/index.html?query=Microbiome)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Microbiome developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Microbiome) ^{<a href="#ref-2">[2]</a>}

See Also

• [astrocytes](/cell-types/astrocytes)
• [alpha-synuclein](/proteins/alpha-synuclein)
• [Huntingtin ([HTT](/proteins/huntingtin)[/proteins/[huntingtin](/proteins/huntingtin) ^{<a href="#ref-3">[3]</a>}

Microbiome-Brain Axis

References